Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure
AssigneePfizer Inc.
InventorsVishwas M. Paralkar, David D. Thompson
Life of this patent
Estimating the term…
Abstract
This invention is directed to methods and compositions of treating acute or chronic renal failure or dysfunction, or conditions caused thereby, comprising administering prostaglandin agonists, which are EP4 receptor selective prostaglandin agonists.
Claims18
A method of treating acute or chronic renal failure or dysfunction, or a condition caused thereby, in a mammal comprising administering to said mammal an EP4 receptor selective agonist, an isomer thereof, a prodrug of said agonist or isomer, or a pharmaceutically acceptable salt of said agonist, isomer or prodrug.
A method of using a pharmaceutical composition comprising a compound which is a selective EP4 receptor agonist, an isomer thereof, a prodrug of said agonist or isomer, or a pharmaceutically acceptable salt of said agonist, isomer or prodrug, together with a physiologically acceptable diluent, carrier or vehicle, for the treatment of acute or chronic renal failure or dysfunction, or a condition caused thereby, in a mammal.
Dependencies are inferred from the claim text.